VIVUS, Inc. (VVUS) Analysts See $-0.11 EPS

October 13, 2018 - By Louis Casey

Investors sentiment decreased to 0.69 in 2018 Q2. Its down 0.31, from 1 in 2018Q1. It fall, as 10 investors sold VIVUS, Inc. shares while 16 reduced holdings. 11 funds opened positions while 7 raised stakes. 18.50 million shares or 15.99% less from 22.03 million shares in 2018Q1 were reported.
Citigroup Incorporated reported 1,150 shares. Benjamin F Edwards And reported 200 shares. Moreover, Commercial Bank Of Montreal Can has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). Northern Trust Corp has invested 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Vanguard Grp Inc stated it has 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Commerzbank Aktiengesellschaft Fi holds 24,000 shares or 0% of its portfolio. Caprock Gru owns 28,000 shares. First Tru Advisors Limited Partnership holds 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS) for 112,975 shares. Royal Bancorp Of Canada, Ontario – Canada-based fund reported 271,401 shares. State Street Corp holds 103,137 shares or 0% of its portfolio. Millennium Limited Company holds 42,655 shares. Sg Americas Secs Limited Liability Corporation owns 20,175 shares. Gru One Trading Limited Partnership owns 35,868 shares. Citadel Advsrs Limited Liability, a Illinois-based fund reported 25,947 shares. Renaissance Techs Limited Liability Corp owns 7.85M shares.

Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report $-0.11 EPS on November, 6.They anticipate $0.05 EPS change or 83.33 % from last quarter’s $-0.06 EPS. After having $-0.12 EPS previously, VIVUS, Inc.’s analysts see -8.33 % EPS growth. The stock increased 4.18% or $0.19 during the last trading session, reaching $4.74. About 59,621 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 38.95% since October 14, 2017 and is downtrending. It has underperformed by 54.57% the S&P500.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $50.50 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

More news for VIVUS, Inc. (NASDAQ:VVUS) were recently published by:, which released: “VIVUS to Present at the BIO Investor Forum on October 17, 2018” on October 10, 2018.‘s article titled: “VIVUS Regains Compliance with Nasdaq Listing Requirements” and published on September 26, 2018 is yet another important article.

VIVUS, Inc. (NASDAQ:VVUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.